__MAIN_TEXT__

Page 1

Prevail INNOVATION & IMPACT

ANNUAL REPORT 2017


Innovation

/in路no路va路tion/ noun the introduction of something new

Impact

/im路pact/ verb to have a strong effect on someone or something


T

o prevail over cancer is the sole focus of Fox Chase Cancer Center—an ideal clearly stated in our mission. However, mission statements are simply words. To understand the character of an institution, one must look deeper. How do its people turn words into action? How does performance become achievement? As one of the nation’s first cancer hospitals, Fox Chase has a rich history of innovation and discovery. For decades, our clinicians and researchers have led their fields in advancing what we know and understand about cancer. Their work has fueled the national conversation about how to approach prevention and treatment. Throughout the pages of this year’s annual report, in addition to highlighting our achievements from the past fiscal year, we follow the Center’s impressive timeline, noting some of the milestones that have spurred dramatic improvements in survival and quality of life for so many people. To sustain achievement of this caliber over so many years, an institution must employ brilliant minds. From the time of our founding more than a century ago, Fox Chase faculty members have been among the very brightest. What sets our entire staff apart is the sheer dedication they bring to reaching ever-loftier goals—not for the accolades and honors they earn, but for you, your family, your friends. Our patients know it, but more than that, they feel it. As we look back on the year, it becomes clear that our work can be daunting. Cancer destroys, and we do all we can to prevail. In treating people with this disease, we are not satisfied with the status quo. Instead, we build on our legacy as we ask new questions and look for the next breakthroughs. For us, innovation comes from collaboration. We draw from the strength of many to achieve the greatest impact. We venture into the unknown, pursue a new idea,

Cancer destroys, and we do all we can to prevail. In treating people with this disease, we are not satisfied with the status quo. Instead, we build on our legacy as we ask new questions and look for the next breakthroughs. For us, innovation comes from collaboration.” — Richard I. Fisher, MD

P R EVA I L

I NNOVAT I O N & I M PACT

1


1904 On October 8, a group of Philadelphia physicians and businessmen, concerned with rising cancer rates in the city, signed the charter establishing the American Oncologic Hospital, one of the country’s first hospitals devoted exclusively to treating cancer. The new hospital opened on January 4, 1905, in a converted Victorian home at 45th and Chestnut streets in West Philadelphia. In its first year, it admitted 206 patients. Public perception of cancer at the time was that most cancers were incurable, contagious, and caused by trauma. The word cancer itself was largely taboo outside the medical field.


develop a novel study, or rethink a prior approach. When we do this, cancer retreats. In fiscal year 2017, we made important strides in high-impact areas across our organization. A number of recruitment successes, along with notable changes in leadership of key areas, further boosted our respected faculty and staff. In addition, we made significant enhancements to the patient experience on our campus and saw marked results in process improvement initiatives. Our clinical programs achieved important advances. Our institution and many individuals earned various honors. Our marketing campaign powerfully told the story of the choices our patients face, and our generous donors made a true philanthropic impact.

PHOTO COURT ESY OF FOX CHASE CANCER CENTER ARCH IV ES

Core Grant Renewal

Kicking the year off on a high note, we received confirmation that Fox Chase attained a successful five-year renewal of our Cancer Center Support Grant (CCSG), or Core Grant, from the National Cancer Institute (NCI). This achievement carries on our long-standing legacy of excellence as one of the few institutions to hold continuous CCSG funding since 1974, when the NCI first started providing this support. The Core Grant provides the backbone for the full breadth and depth of research activities within our institution, including laboratory, clinical, and population-based research. Perhaps even more notable is the grant’s significance. It gives us our elite status as an NCI-designated Comprehensive Cancer Center—a distinction held by only 49 institutions across the country. It affirms our high caliber of research and life-saving clinical trials, allows us to recruit top researchers and clinicians, inspires donors to support our work, and attracts patients and families who choose us for their care.

Recruitment Successes and Clinical Achievement

Among my highest priorities as president and CEO is the recruitment and retention of talented faculty and staff. This year proved particularly fruitful, as we welcomed a number of exceptional additions, including a major recruit to direct our financial strategy as well as leaders in crucial areas within our clinical enterprise. Chief among this year’s faculty recruits is Martin J. Edelman, MD, who fills a key leadership position as Chair of the Department of Hematology/Oncology. His charge is to collaborate across the institution to grow robust therapeutic, clinical research, and translational research programs in

1925 Stanley P. Reimann, MD, Lankenau Hospital’s chief pathologist, founded the Lankenau Hospital Research Institute. His research was driven by his belief that understanding cancer requires understanding normal cell growth and development. In 1945 it would evolve into the Institute for Cancer Research.

P R EVA I L

I NNOVAT I O N & I M PACT

3


1933 The newly formed Anna M. Gray Auxiliary, the forerunner to Fox Chase’s Board of Associates, held the first “annual cancer forum” for the public. The forum included a lecture, a luncheon, and a tour of Reimann’s Institute. Admission cost 50 cents. About 150 people attended the event.

4

FOX C HA S E CA N CER CEN T ER

Having successfully emerged from a period of financial challenge with significant momentum, Fox Chase is poised to build on renewed stability and strength. Our new Chief Financial Officer Ray Lynch, MBA, CPA, offers a unique mix of expertise that will propel Fox Chase’s vision and progress. Equally important, he understands the special demands of protecting and advancing the financial interests of a NCIdesignated institution. In his new role, Lynch directs the financial operations, designing and executing strategic financial plans and initiatives to position Fox Chase for continued achievement of clinical, research, and academic goals. Prior to joining Fox Chase in the spring of 2017, he spent 13 years as the executive director at the Huntsman Cancer Hospital, the clinical arm of the Huntsman Cancer Institute at the University of Utah. As senior administrative leader, Lynch oversaw operations, safety and quality, finance, and strategic and programmatic planning. Lynch earned his bachelor’s degree in journalism at the University of Missouri – Columbia and an MBA from Baylor University. He serves as Treasurer of the National Comprehensive Cancer Network (NCCN) Foundation Board of Directors and has served as a member of the Executive, Governance, and Finance committees of the NCCN Board of Directors.

A N N UA L R EP O RT 2 01 7

• Henry Fung, MD, FACP, FRCPE, is now Chief of the Section of Hematologic Malignancies, and continues to direct the Bone Marrow Transplant Program and expand the research division into appropriate areas including cellular therapies. • Anthony Olszanski, MD, RPh, is Chief of the Section of Solid Tumor Oncology, leading efforts to improve multi-modality care and to introduce new treatments. • Paul F. Engstrom, MD, FACP, is Chief of the Section of General Hematology/Oncology with responsibility for expanding general hematology/oncology consultative services at Fox Chase and Jeanes Hospital as well as outpatient services at Fox Chase, Jeanes, and other allied facilities. • Deric Savior, MD, serves as Head of Medical Oncology at Fox Chase Cancer Center at Temple University Hospital, leading improvement and expansion of medical oncology services at Temple with a major focus on clinical trial accrual and other research efforts. We also added new members to the Department of Hematology/Oncology including Philip A. Pancari, MD, who joined us after completing a hematology/oncology

PHOTO COURT ESY OF FOX CHASE CANCER CENTER ARCH IV ES

New Financial Leadership

hematology and medical oncology while leading the department in evaluating emerging national trends in cancer care. With the appointment of Ray Lynch, MBA, CPA, to the role of Chief Financial Officer, we have a seasoned finance professional with significant operations experience—a unique mix of expertise that will enhance our capacity for future innovation and impact. Recent recruits Roman V. Petrov, MD, and Yanis Boumber, MD, PhD, add strength to our already well-regarded thoracic cancer program. Petrov is a fellowship-trained surgeon with clinical interests in lung cancer, esophageal cancer, benign foregut and gastroparesis, mediastinal tumors, chest wall tumors and deformities, thoracic outlet syndrome, and hyperhidrosis. Boumber, of our department of thoracic medical oncology and the Molecular Therapeutics Program, specializes in treating patients with lung cancer, thymoma, and mesothelioma. I expect the combination of these impressive figures to further advance our reputation and support our growing lung cancer program. In his first year, Edelman has outlined a new structure for the Department of Hematology/Oncology, organizing it into four sections to maximize our potential and appointing key leaders on our faculty to advance these efforts.


During 27 years of working in top-tier cancer organizations, Fox Chase has always been a name symbolic with the very best of the best.” — Ray Lynch, MBA, CPA


1947 The Institute for Cancer Research held a ground-breaking ceremony on June 5 for its new home in the Fox Chase neighborhood of Philadelphia. The 14,000 square-foot facility, built with funds from the Pew family, will house, “about 100 research workers divided into working groups in various fields, all headed toward a reasonable solution of the cancer problem,” wrote architect Vincent G. Kling in the ceremony’s program. The building was named for Stanley Reimann in the early 1990s.

6

FOX C HA S E CA N CER CEN T ER

A nationally renowned expert in the research and treatment of lung cancer, Martin J. Edelman, MD, brings a wealth of experience and knowledge with him to Fox Chase Cancer Center. As Chair of the Department of Hematology/Oncology, Edelman leads Fox Chase’s dedicated team of medical oncologists. He also serves as deputy cancer center director for clinical research, leading the effort to integrate discoveries from the Translational Research Initiative into a program of strong investigator-initiated clinical trials. After receiving his medical degree from Albany Medical College, Edelman completed residency training in internal medicine and a hematology/ oncology fellowship at Naval Medical Center San Diego. His achievements in oncology include developing one of the most commonly used regimens for treating advanced lung cancer and working toward the development of new agents and biomarkers to personalize lung cancer therapy. In addition to clinical and leadership achievements, Edelman has been a prolific author, publishing more than 325 scientific articles, abstracts, and book chapters. He currently serves as deputy editor of the journal Lung Cancer. Edelman served for more than 20 years in the United States Navy Reserve, retiring with the rank of Captain. During his active service, Edelman worked aboard the USS Duluth (LPD-6) as senior medical officer.

A N N UA L R EP O RT 2 01 7

fellowship at Temple University Hospital and Fox Chase Cancer Center. He provides additional physician support for the Fox Chase Temple University Hospital Bone Marrow Transplant Program. Also new to this department is Molly E. Collins, MD, who provides added physician support for our Pain and Palliative Care Program, a well-established and growing program through which practitioners collaborate with all departments, including medicine, surgery, radiation oncology, and psychiatry, as well as across professions. We have sharpened our focus in this area with the development of a new Hospice and Palliative Medicine fellowship in partnership with the Hospice of the Visiting Nurse Association of Greater Philadelphia (VNA) and Temple University Hospital. Palliative care includes expertise in pain and symptom management, communication, complex psychosocial, and end-of-life care. Although recognized as an integral part of high-quality cancer care, there is a nationwide shortage of experienced practitioners. Our fellowship, which is approved by the Accreditation Council for Graduate Medical Education, will address a growing need and places Fox Chase at the forefront of a national trend to offer specific training to the next generation of clinicians. Fellows will benefit from exposure to a wide range of patients with serious illnesses, practicing palliative care with experienced interdisciplinary teams. We also partnered with the Visiting Nurse Association of Greater Philadelphia to formalize our inpatient hospice program. Spearheaded by Chief Medical Officer James Helstrom, MD, MBA, this move further enhances our supportive care offerings for patients at the end of life, when comfort measures are indicated as the most appropriate course of care. Patient care is managed exclusively by Fox Chase clinical staff and administratively rendered under the VNA’s hospice designation. The program benefits our patients and their families with on-site supportive care by our team of specialists, expanded visitation rights, and access to extended bereavement services through the VNA. This measure is part of a larger effort to enhance overall continuity of care for Fox Chase patients. Our Department of Medicine welcomed a variety of practitioners. Dermatologist Abhishek Aphale, MD, specializes in Mohs surgery and reconstruction and cutaneous oncology. His research interests include squamous cell carcinoma, basal cell carcinoma, melanoma, and rare cutaneous tumors. Gastroenterologist Michael Bartel, MD, specializes in liver, gall

PHOTO COURT ESY OF FOX CHASE CANCER CENTER ARCH IV ES

Edelman Helms Hematology/ Oncology


In my first eight months at Fox Chase I have been impressed by the quality and courtesy of the entire staff. This is truly a unique place.� — Martin J. Edelman, MD


1959

Fox Chase doctoral student David A. Hungerford, MD (R) and Peter C. Nowell, MD (L), from the University of Pennsylvania, discovered what would become known as the Philadelphia Chromosome. It was the first conclusive evidence that cancer is a genetic disorder of somatic cells, and it was the first scientific discovery that led to the development of a targeted cancer therapy.

8

FOX C HA S E CA N CER CEN T ER

A N N UA L R EP O RT 2 01 7

PHOTO COURT ESY OF FOX CHASE CANCER CENTER ARCH IV ES

bladder and bile duct cancer, pancreatic cancer, and stomach cancer. Paula H. Finestone, PhD, is an attending clinical psychologist experienced in working with both inpatients and outpatients facing cancer and other serious diagnoses as well as providing education and support for family members and other caregivers. Christopher J. Manley, MD, is Director of Interventional Pulmonology and brings expertise in pulmonary and critical care medicine. He performs minimally invasive procedures to diagnose and treat lung cancer, benign and malignant causes of airway obstruction, and pleural disease, and provides care to patients who require the intensive care unit (ICU). Finally, Kristen J. Scully Manley, MD, joined our hospitalist service to provide care to patients requiring acute care hospitalization. In our Department of Pathology, we recruited Shuanzeng (Sam) Wei, MD, PhD, who specializes in surgical pathology and cytopathology. Rajeswari Nagarathinam, MD, who focuses on both surgical pathology and cytopathology, also joined our pathology team after finishing a surgical oncologic pathology fellowship at Fox Chase. In the Department of Surgical Oncology, Allison A. Aggon, DO, brings expertise in breast surgery, focusing exclusively on patients with breast cancer, those at high risk for it, and those with complex benign breast conditions. For several years, the Department of Radiation Oncology has helped to pioneer an advanced treatment technique called hypofractionation, or hypofractionated radiation therapy. For patients who qualify, hypofractionation significantly reduces the number of treatments needed compared to conventional radiation therapy. After extensive study, including large clinical trials at Fox Chase, it has proven to be just as safe and effective, with the possibility of fewer short term side effects and a better quality of life for our patients. This was the year in which hypofractionation truly became the standard of care for lung, breast, and prostate cancer. Fox Chase continues to be a leader in developing new cancer therapies. The department also added Krisha J. Howell, MD, who specializes in treating patients with cervical cancer, endometrial (uterine) cancer, head & neck cancer, ovarian and primary peritoneal cancer, sarcoma, uterine sarcoma, and vulvar cancer. Within our research enterprise, Joan Font-Burgada, PhD, joined our faculty as Assistant Professor in the Cancer Biology Program. A researcher who works on liver cancer and regenerative medicine, Font-Burgada is a current recip-


Scientific acumen, compassion, and empathy are the requisite traits of an oncologist. At Fox Chase, we strive to uphold these values for the benefit of our patients.� — Deric C. Savior, MD


1965 The Board of Associates was founded. Today the Board is comprised of four member organizations and four affiliates, harnessing the passion, creativity, and generosity of more than 300 volunteers—many of whom are motivated by experiences with cancer. Since 1965 the Board has raised more than $22 million for research and patient care at Fox Chase through independently organized fundraisers such as community events, dinners, trips, shows, and vendor sales.

10

Continuing a period of significant growth for the institution, Fox Chase opened a new pharmacy in March 2017. The pharmacy provides resources that help complement patient care. It serves Fox Chase outpatients and inpatients who are being discharged. The facility carries a wide range of medications frequently used in cancer care, including oral cytotoxic specialty drugs, and other medications not often available in local retail pharmacies. With a pharmacy on site, doctors and nurses can rest assured that their patients will be able to go home with their prescriptions in hand. The pharmacy team has access to patients’ admissions and medical records, enabling them to quickly check for interactions with other medications the patient may be taking. Additionally, one member of the pharmacy team focuses solely on insurance issues. The convenient location of the pharmacy near the West Parking Garage means that patients don’t have to worry about making another stop after they leave Fox Chase. The pharmacy is designed to be an integrated part of the patient’s visit. By the time the patient has completed their visit and is ready to leave, the prescription will be ready. The pharmacy was celebrated with a ribbon-cutting ceremony in April.

FOX CHA S E CA N CER CEN T ER

A N N UAL R EP O RT 20 17

Advanced Training

As more staff members join our ranks, we are also working to train the next generation of clinicians and researchers. In our general surgery division, Fox Chase began a new summer medical student program, accepting four summer students this year. In addition to the new Hospice and Palliative Medicine fellowship, Fox Chase received approval from the American Head and Neck Society to offer a new fellowship in Advanced Head and Neck Oncologic Surgery. With the creation of these fellowships, we will be able to offer training and guidance to physicians while continuing to provide stellar care to our patients. In our nursing division, the Nursing Evidence-Based Practice and Research Council held its first Clinical Nurse Scholars Program, designed to mentor clinical nurses in developing evidence-based practice projects. This program specifically addressed professional development needs that were voiced by the clinical nurses at Fox Chase and was developed to mentor nurses and help create networking and mentorship opportunities across departments to enhance relationships.

In the Community

Although they make a difference every day at work, many of our staff members have also made an impact in the community. Nurses from a range of departments prepared and served dinner for guests staying at the nearby AstraZeneca Hope Lodge of the American Cancer Society, which offers

PHOTO COURT ESY OF FOX CHASE CANCER CENTER ARCH IV ES

Fox Chase Rolls Out New On-Site Pharmacy

ient of the prestigious National Cancer Institute Pathway to Independence Award, a grant that helps highly accomplished postdoctoral researchers complete their training and transition to a faculty position. John Karanicolas, PhD, joined Fox Chase as an Associate Professor in the Molecular Therapeutics Program and brings particular expertise in computational chemistry. His lab focuses on drug discovery for non-traditional therapeutic targets. Finally, Scott Shepard, MD, joined the medical staffs of Fox Chase Cancer Center and neighboring Jeanes Hospital. He also is an Associate Professor of Clinical Neurosurgery at the Lewis Katz School of Medicine at Temple University. He specializes in neurosurgical oncology, benign and malignant brain tumors, meningiomas, stereotactic radiosurgery of the brain and spine, Gamma knife radiosurgery, and neurosurgical critical care.


Patients often tell me they feel a difference when they walk through our doors. I felt it too when I started working here. It reflects a culture of kindness and caring, and in particular unparalleled nursing advocacy for patients. I am very grateful to collaborate every day with colleagues for whom this work is their calling.� — Molly E. Collins, MD


Carolyn Y. Fang, PhD

Alexander Kutikov, MD, FACS

Joshua E. Meyer, MD

Andrew J. Andrews, PhD

12

FOX C HA S E CA N CER CEN T ER

A N N UA L R EP O RT 20 17


Rising Stars

Harvey Hensley, PhD

Carolyn Y. Fang, PhD, co-leader of Fox Chase’s Cancer Prevention and Control research program, was promoted to the position of professor with tenure. Fang’s research interests include psychosocial and behavioral factors associated with cancer prevention, risk management and survivorship. She also studies biobehavioral pathways in stress and health, including stress-related immune dysregulation in at-risk and cancer patient populations, and community-based interventions to reduce cancer health disparities in Asian Americans. She joined the faculty at Fox Chase in 1997. Alexander Kutikov, MD, FACS, a surgical oncologist, was promoted to the position of professor in the Department of Surgical Oncology at Fox Chase. Kutikov, who treats bladder, kidney, prostate, testicular, and urethral cancers, was also promoted to chief of the Division of Urology and Urologic Oncology. He joined the faculty at Fox Chase in 2010 after completing a Society of Urologic Oncology Fellowship at the Center. Harvey Hensley, PhD, manager of the Small Animal Imaging Facility, was promoted to the position of associate research professor. Trained as a physicist, Hensley has applied imaging methods to the study of cancer in vivo in preclinical models, and has overseen the expansion of the facility from one modality (MRI) to include optical, endoscopic, and nuclear imaging methods. He joined Fox Chase in 1998.

Joshua E. Meyer, MD, a radiation oncologist, was promoted to the position of associate professor and is now Vice Chairman of Translational Research in the Department of Radiation Oncology. Meyer, who treats neuroendocrine tumors and colorectal, esophageal, liver, lung, pancreatic, stomach, and gall bladder and bile duct cancers, joined Fox Chase in 2010. He also served as director of the Radiation Oncology Residency and Fellowship Training Program. Andrew J. Andrews, PhD, a member of the Center’s Cancer Epigenetics research program, was promoted to associate professor with tenure. His research interests include the specificity of enzymes responsible for the post-translational modification of histones, with a primary focus on histone and acetylation, its impact to chromatin dynamics in addition to developing targeted analytical method for biological applications. He joined Fox Chase in 2010. Jinhua Wu, PhD, a member of Fox Chase’s Molecular Therapeutics research program, was promoted to the position of associate professor with tenure. Wu’s research interests include structural and functional studies of integrin signaling, including structural basis to the regulatory mechanisms of the inside-out integrin signaling, structural and functional analyses of the MRL family proteins, and development of anti-talin inhibitors by structure-based computer-aided design. He joined the faculty at Fox Chase in 2010.

Jinhua Wu, PhD

P R EVA I L

I NNOVAT I O N & I M PACT

13


Late 1970s

lodging at no cost for out-of-area cancer patients. Guests must provide their own food and are often faced with limited options such as take-out or food from a hospital cafeteria. Our nurses sponsored the dinner and delivered homecooked meals to the guests. We also continued to grow our “Together Facing” series, which brings together clinicians, researchers, patients, caregivers, and industry partners for a night of disease-specific education. During these programs, experts discuss the latest treatment options while patient speakers share their inspirational stories. Patients and their guests have the opportunity to ask questions, interact with one another, and learn about advocacy opportunities. This year, we hosted Together Facing events for lung cancer, sarcoma, pancreatic cancer, and gynecologic cancers. Next year, we will add gastrointestinal stromal tumors (GIST), colorectal cancer, melanoma and other skin cancers, breast cancer, hematologic cancers, and genitourinary cancer. The true measure of our work is the patient experience. When someone chooses to be treated at Fox Chase Cancer Center, we want to honor this trust by providing an outstanding experience. To this end, we have made significant progress, which can be seen in both our facilities and services.

Fox Chase’s Irwin A. Rose, PhD (L), and collaborators Avram Hershko, MD, PhD, and Aaron Ciechanover, MD, PhD, discovered one of the cell’s most important metabolic processes: how proteins are broken down and recycled. Their discoveries established a new paradigm in biology and formed the basis for Velcade, a drug later approved for multiple myeloma. The three would go on to receive the Nobel Prize in Chemistry in 2004.

Perhaps one of the most visible signs of this commitment is the opening of the Fox Chase Cancer Center Pharmacy. The onsite facility serves Fox Chase clinic patients and inpatients, carrying a range of medications, including oral cytotoxic specialty drugs often not readily available in local retail pharmacies. In addition to convenience, it will increase compliance with follow-up care by ensuring that patients have ready access to needed medication.

Infusion Care Management

In addition, we made strategic operational changes in our busy infusion room. The work was prompted by feedback from our patients and focused specifically on addressing the long wait times for chemotherapy appointments. Vice President of Ambulatory Care Maureen McDade led this effort and along with her team, partnered with the company LeanTaas to launch new software that lets us take a big-picture look at how we use resources. The software analyzes staffing, hours of operation, appointment history, and other factors. By more closely studying our daily infusion activity

14

FOX CHA S E CA N CER CEN T ER

A N N UAL R EP O RT 20 17

PHOTO COURT ESY OF FOX CHASE CANCER CENTER ARCH IV ES

Opening of Onsite Pharmacy


and making real-time adjustments based on usage, we created a more realistic schedule that better serves our patients, families, and staff. The new process has seen much success. Since the rollout in November 2016, there has been a 52 percent decrease in average wait time during the busiest hour (12 to 1 p.m.) and a 53 percent decrease in average wait time during peak hours (10 a.m. to 3 p.m.). Overall, there has been a 48 percent decrease in wait times. Press Ganey comments, which independently track patient satisfaction, have reflected a substantial increase in positive feedback related to the change.

Reimagined Patient and Caregiver Comfort

When waiting is part of a family’s experience—for example, when a loved one is in surgery—we want to make the time comfortable. This year, we marked the unveiling of the Marian and Emma Brungard Surgical Family Waiting Suite—a project made possible by the generosity of individuals who supported the special pledge at the 2015 In Vino Vita Benefit and Wine Auction, as well as the Brungard Family through the Estate of Marian Brungard. The new waiting room is more than twice the size of our former space and features three private consult rooms, access to natural light, more varied seating including Wi-Fi workstations and charging stations, a private restroom, an improved snack area, secure storage lockers, regular staffing by the volunteer office, and a HIPAA-compliant electronic board that shows the progress for each family’s loved one. In addition, the use of pagers allows family members to freely move about campus and still be reached by clinical staff. Keeping our patients comfortable is of the utmost importance to our staff. One way we make an impact here is by managing the physical side effects of treatment. Funded by a $12,000 grant from TEVA Pharmaceuticals, our volunteer department created hundreds of handmade blankets to give to patients who needed to keep warm during chemotherapy infusions.

COLIN LENTON

Process Improvement in Supply Chain

In terms of operational efficiencies, we joined Temple University Health System in partnering with the Cleveland Clinic and other academic centers to standardize supply purchasing in a program called Excelerate. This sourcing program allows members to secure best-in-class contracts for clinical products and services. It covers purchasing for

Where You Start Matters Fox Chase launched a powerful new advertising campaign to communicate that starting treatment here gives people the best chance for a positive outcome. The “Where You Start Matters” campaign concept is based on published data showing that patients with all cancer types have a better chance at long-term survival if they start their care at a specialized cancer center. With an attention-grabbing documentary feel, the print and broadcast ads featured real cancer survivors Brooke Fuller, Todd Jackman, Lawrence James, and Linda Snow telling their personal stories in their own words. Each individual talked about how coming to Fox Chase for their earliest treatment decisions affected their prognosis. In an accompanying ad, Fox Chase President and CEO Richard I. Fisher, MD expanded on the theme by discussing specific advantages Fox Chase provides to patients, including the opportunity to be treated by some of the best cancer sub-specialists in the country. The advertising campaign was featured prominently throughout the region, in newspapers, billboards and other outdoor advertising vehicles, television, and radio. Market research indicates that Fox Chase is already the most recognizable brand for people thinking about cancer care in the Philadelphia region. Where You Start Matters helped highlight Fox Chase’s unique capabilities, further building the Center’s reputation.

1991

P R EVA I L

Fox Chase scientists Joseph Testa, PhD (R), and Alfonso Bellacosa, MD, PhD (L), identified the protein AKT as a major driver of cancer development. AKT hinders the process by which the body kills abnormal cancer cells. The findings were the first evidence of a recurrent genetic alteration in a cell signaling pathway playing a central role in tumor development. More than 50,000 papers have been published on AKT, and a number of potential targets for future anti-cancer drugs have been found based on this work.

I NNOVAT I O N & I M PACT

15


Greenberg’s Gift This year Philadelphia philanthropist and longtime friend of Fox Chase, Concetta Greenberg, entered into an agreement to make a transformational gift through the creation of The Marvin and Concetta Greenberg Pancreatic Cancer Institute. Fox Chase is a renowned leader in pancreatic cancer, having earned designation as a National Pancreas Foundation Center. This multi-milliondollar commitment, the largest single gift in Fox Chase history, will elevate the Center’s work in pancreatic cancer research and treatment. With pancreatic cancer expected to become the second leading cause of cancer death by 2030, the need for greater impact is urgent. Igor Astsaturov, MD, PhD and Edna Cukierman, PhD, both of whom are accomplished pancreatic cancer researchers, will co-lead the new institute. Their shared goal is to develop innovations in early detection and new treatment options. Astsaturov is also an oncologist who specializes in treating pancreatic and other gastrointestinal cancers. Fox Chase physicians Efrat Dotan, MD, Sanjay Reddy, MD, and Crystal Denlinger, MD, will continue to play key roles in patient care in this population. Since losing her husband to pancreatic cancer in 2005, Greenberg has been committed to eradicating the disease. In 2008, she established the Marvin S. Greenberg, MD, Endowed Chair in Pancreatic Cancer Surgery, which is currently held by John P. Hoffman, MD, chief of the pancreaticobiliary service at Fox Chase and honorary member of the new institute. Igor Astsaturov, MD, PhD

16

FOX CHA S E CA N CER CEN T ER

A N N UAL R EP O RT 20 17


Edna Cukierman, PhD

P R EVA I L

I NNOVAT I O N & I M PACT

17


Take the Lead

1995

Fox Chase became a founding member of the National Comprehensive Cancer Network, an alliance of leading academic cancer centers, designed to ensure high-quality, cost effective care based on uniform treatment guidelines. Robert Carlson, MD, is the current CEO and a physician at Fox Chase.

18

Under the leadership of Dan Levin, CIMA®, CPWA®, the Board of Associates is poised to grow in new directions. In January 2017, Levin began a two-year term as president of the coalition of dedicated Fox Chase supporters. A private wealth advisor by profession, Levin is the co-founder and Executive Vice President of 1776 Capital Management Group at Janney Montgomery Scott in Blue Bell, Pa., and has a longstanding history of support for Fox Chase. Several years ago when he was seeking a way to get involved as a volunteer in his community, Levin became a supporter of Fox Chase on the recommendation of a family friend and mentor. He joined the Bucks County chapter, and upon seeing how the money they raised directly impacted research projects at Fox Chase, he decided to take on a bigger role in fundraising. Before becoming president of the Board, he first served as vice president and president of the Bucks County chapter. During his tenure, Levin will seek to increase the number of chapters and members who participate in the Board. He also has a particular focus on engaging younger people in order to cultivate the next generation of fundraisers and donors.

FOX CHA S E CA N CER CEN T ER

A N N UAL R EP O RT 20 17

everything from specialty surgical equipment to generic supplies such as gloves and catheters. Chief medical officers, including James Helstrom, MD, MBA, at Fox Chase, are strategically leading this system-wide effort with supply chain professionals managing the logistics and contracts while clinicians make purchasing decisions about products and equipment. Patient safety and product quality are top priorities. Already, we have realized substantial cost savings to Fox Chase, which frees us to channel resources to other priority initiatives.

Accolades and Honors

Our tradition of excellence is really a legacy of innovation and impact. Fox Chase Cancer Center and its faculty and staff earned multiple accolades over the last year in recognition of a wide range of achievements. These honors included full reaccreditation from the Commission on Cancer (CoC) of the American College of Surgeons. This voluntary accreditation requires cancer programs to meet 34 quality care standards, be evaluated every three years through a survey process, and maintain levels of excellence in the delivery of comprehensive patient-centered care, including prevention, early diagnosis, staging, treatment, rehabilitation, life-long follow-up for recurrent disease, and end-of-life care.  U.S. News & World Report recognized Fox Chase as #28 among the top institutions for cancer care in its 2017 Best Hospitals list. These annual rankings have come to be regarded by consumers as an important guide that informs decisions about where to seek medical care. Rankings are calculated based on factors including a national survey that asks doctors to rate hospitals on reputation as well as patient safety measures, Magnet nursing status, and outcomes metrics. In addition, the Center was recognized for the second consecutive time in the area of Ear, Nose, and Throat Care with a national ranking of #40. Finally, our urology and nephrology care also received high performing marks from the magazine. Along with these institutional honors, our clinicians are routinely recognized for their individual contributions. A prime example is Philadelphia magazine’s annual Top Doctors issue which included 37 Fox Chase physicians—about half the total number of recognized physicians from Temple Health. The list is notable because it features physicians from a range of specialties who were selected among the region’s best by a national survey of their professional peers.


The volunteers draw strength from knowing they are working on something special, and they joyfully dedicate many precious hours of their lives to raise money and awareness for this great hospital and cause. — Dan Levin, CIMA®, CPWA®


Strength in Branding

Our brand, already considered the most recognized for cancer in the Philadelphia region, continues to flourish. This includes evolving into the oncology brand for all of Temple Health. Our latest move in this direction involved the rebranding of hematology-oncology services and the infusion center at Temple University Hospital’s Northeastern Campus as Fox Chase Cancer Center at TUH-Northeastern Campus. The change gives cancer patients at Northeastern access to both TUH’s and Fox Chase’s medical and surgical subspecialists, as well as all appropriate treatment protocols and clinical trials offered at both Fox Chase and TUH. In addition to maximizing the growth of oncology and related services, the combined expertise of clinicians on the Fox Chase, TUH Broad Street and TUH-Northeastern campuses expands opportunities for research in the causes, detection, and treatment of cancer. This rebranding follows two milestones that took place in 2015 in which TUH Cancer Center was renamed Fox Chase Cancer Center at Temple University Hospital and TUH’s Bone Marrow Transplant program (located on the campus of Jeanes Hospital) was renamed the Fox Chase Temple University Hospital Bone Marrow Transplant Program. All of these changes more closely link resources and expertise across campuses, enhancing the provision of coordinated cancer care throughout Temple Health. To promote our Center, we launched a powerful campaign to communicate to consumers that “where you start matters”—a concept based on published data demonstrating that patients have a better chance of survival if they start their cancer care at a specialized cancer center.

2010

In an effort to improve the patient experience, Fox Chase launched its Nurse Navigation program, first piloting the initiative with two breast cancer navigators. Within five years, the program had expanded to include 16 navigators in 10 disease areas, and now serves as an example for healthcare institutions nationally. Fox Chase navigators, who are all certified oncology nurses, help patients throughout the entire treatment process, providing education, reducing barriers, and connecting them to needed services and resources.

20

FOX CHA S E CA N CER CEN T ER

Several years ago our Institutional Advancement team introduced a signature event to form the cornerstone of our fundraising efforts. The In Vino Vita Auction and Wine Benefit has grown dramatically in just four years to become Philadelphia’s premier wine auction. We set another record this year by raising $2M for Fox Chase—double the amount raised in the previous year—and we’re looking to achieve an even greater number on April 21, 2018. More and more, the impact of private philanthropy proves vital for an institution such as ours as federal funding becomes scarcer. In Vino Vita’s special pledge this year provides pilot funds for young investigators. With great

A N N UAL R EP O RT 20 17

JOSEPH HURLEY

Philanthropic Success


2016

JOSEPH HURLEY

competition for government grants and stringent guidelines from federal agencies, investigators must overcome serious challenges to prove the potential of their research. Private funding often can support innovative and sometimes riskier ideas, providing opportunities for researchers to gather preliminary data that can lead to additional funding from federal sources. The evening came together in stellar fashion because of the hard work and support of many, including Donald E. Morel, Jr., PhD and Lauren Morel, who served as event chairs; Louis and Carol Della Penna, who offered their guidance as wine chairs; and the entire Institutional Advancement team along with many of our faculty, staff, and boards. Equally exciting, we secured the largest single gift in Fox Chase history this year with a multi-million-dollar commitment by Concetta Greenberg to establish the Marvin and Concetta Greenberg Pancreatic Cancer Institute. Finally, we ushered in new leadership of the Board of Associates, our longtime fundraising partners, with Dan Levin becoming president. Since its founding in 1965, the Board of Associates has raised more than $22M for Fox Chase. Its annual donation this past year alone totaled $288,826, the culmination of countless events and fundraising activities. I look forward to even greater success under Dan’s leadership. To look at all we accomplished together this year is to realize that Fox Chase Cancer Center prevails because of its people—our clinicians and researchers, our staff, and most importantly, our patients and their families. My early impressions have turned to deep conviction because I know from within that this is what keeps our institution relevant. Innovation fuels our longevity, but taking bold action is fruitless without an appreciation for the contributions of our predecessors. And so, with a respectful nod to our history, we forge new paths by pursuing what has not been done before. We look to each other for inspiration and we prepare, yet again, to prevail.

The Fox Chase Temple University Hospital Bone Marrow Transplant Program (BMT) expanded its services by opening a brand new outpatient clinic. The advanced BMT facility offers a sophisticated level of clinical care to both inpatients and outpatients. It has been recognized by several accrediting entities, including the Foundation for the Accreditation of Cellular Therapy and the National Marrow Donor Program.

— Richard I. Fisher, MD

President and CEO at Fox Chase

P R EVA I L

I NNOVAT I O N & I M PACT

21


Donors

FOUNDER’S CIRCLE

$500,000 +

Concetta Greenberg The Estate of Nouvel M. Klages* Lauren & Donald E. Morel, Jr. The Trust of Martha B. Newkirk*

CHAIRMEN’S CIRCLE

$100,000 - $499,999

The Estate of William Barbier* The Estate of Eleanor G. Cheleden* Carol A. & Louis E. Della Penna, Sr. Susan C. & William J. Federici Lee M. & Harvey Gitlin The Estate of Dorrance H. Hamilton* Aurora M. & Timothy P. Hughes, Jr. IAL, Inc. Margot Wallace Keith & Robert E. Keith Gloria Jean & Elvin Luke Lukenbach The Estate of Janet W. Oberhaus* Roberta R. & Ernest Scheller, Jr. Alfred P. West, Jr.

ADVOCATE’S CIRCLE

$25,000 - $99,999

The Estate of Freida W. Alkus* The Estate of Jose E. Barcega* Betty Ann & R. Reginald Bishop Regina & Robert J. Brennan Mary & John D. Burke Gloria E. & Steven A. Ellers Carol & Michael D. Ellis Susan G. & Richard I. Fisher Lucille & Jerry Francesco The Estate of Estelle M. Gold* Renee & Neil F. Hall Susan R. & Michael Holt The Estate of Mary C. Law* Judith & Thomas K. Leidy Sandra G. & David G. Marshall Diane S. & Christian F. Martin Nancy & Benjamin Shein Joann Shimko Mike Shimko Debra T. & Leo M. Sniger

22

Tania & Robert Stutman Ruth Weber

CHAMPION’S CIRCLE

$10,000 - $24,999

Anonymous Sharon & William J. Avery Maggie & Bob Beck Michael Bienenfeld Cindy & Jack Bienenfeld Lucy S. Binder Suzanne H. & Frank G. Binswanger, Jr. Claire G. & Bernard A. Borghei Eileen Button Chiachi Chen Mary Ann Sells & Jonathan Chernoff Maureen A. & Gregory A. Church Reina S. & Michael A. Cohen Joan M. & John A. Dietze Edmund M. Dunn Elaine T. Emrick Janet F. & Paul F. Engstrom Mary R. & Joseph Faulkner Karen A. & Michael D. Flynn Donna & Stephen M. Fuga The Estate of Lisa A. Galley* Lori Emrick & Todd J. Glassman Diana Keat & Edward A. Glickman Beverly T. & Stephen M. Godshall Eileen F. & William A. Goldress Marion & Emanuel Golemis Rachel & Eric M. Green Lynn & Brian Hochberg Kay & Thomas W. Hofmann Lisa Kabnick & John McFadden Harry Kalafian* Alice G. & Peter M. Kreindler Patricia & Eric J. Kropf Mary K. & Theodore R. Kulp Jane M. & Kenneth B. Laffend Jeanne Leinen Wendy H. & Solomon C. Luo Betty & Richard D. Luzzi Salli & Stephen R. Mickelberg The Estate of Mary A. Morelli* Leon O. Moulder Jacalyn & William W. Moyer Doreen H. Paynton

FOX CHA S E CA N CER CEN T ER

A N N UAL R EP O RT 20 17

Ann L. & Frank E. Reed Mary D. & Edward J. Roach Debbie & Arthur A. Roedel* Hara & Todd Salkovitz Louise A. Sonnenberg Evelyn J. Swarttz Jane & Robert Toll Lynn Tucker

GUARDIAN’S CIRCLE

$5,000 - $9,999

Anonymous Myra J. & E. Boyd Asplundh Myra & John M. Ballinger, Jr. Maria Barton Delbert E. Broughton, Jr. Lizbeth A. & Ed Brunswick Rose & Michael Carbonara Christine M. Cardamone Karen A. & Jay B. Comly The Estate of Rev. John P. Conte* Judy & Douglas E. Cook Palma & John M. Daly The Estate of Benjamin F. Delong* Margaret & Anthony J. Diasio Evelyn & Wafik S. El-Deiry Sandra Fernandes & Gerard Allen Diane C. & Cameron H. Fowler Amy S. & Joseph A. Frick Cynthia L. & David M. Goldenberg Nancy E. Goldy Donna T. & Lewis F. Gould, Jr. Theresa M. & John R. Greed Richard E. Greenberg Alice M. Hungerford Linda G. & Ivan Inerfeld The Estate of Beryl M. Kiefer* Greta J. Kling Georgia B. & Richard Koenig Kim & Paul Kost Cynthia & Warren Kruger Jessica & Alexander Kutikov Connie & Quintin Lai William H. Lambert Michelle Ludwig Carol & Ray McDonald Michael Meister Carol A. & Thomas Mooney

Lee & Paul O’Hagan The Estate of Kathryn B. Peters* Beatrice Pitcairn Joan E. & Robert R. Pollock Nancy & Stephen J. Rauscher Dolores Renneberg & Larry Sadowniczak Patricia F. Rissler & James A. Rogers Krista & Bryan G. Rogers Anne & Stephen C. Rubin Patricia A. & Bruce A. Ruggeri Janet B. Schell Danielle J. Schroettner Patricia B. & Harris A. Schwartz Ellen L. Sherk Lindy Snider & Larry R. Kaiser Elaine Sykes Frank C. Wilhelm, Jr. Lorraine A. Zacierka

PATRON’S CIRCLE

$2,500 - $4,999

Judith L. Bachman Elinor M. & Ernest* Beier, Jr. Lizanne & Timothy J. Bernlohr Kathleen & Anthony Boccella Dale J. Boychak Elinor & James M. Buck III Laura & Michael J. Callahan Paula & Bob Cardea Frances & James Cardea Theresa R. Clayton Paula & Jason Della Penna Christine & Louis E. Della Penna, Jr. Sharon L. & Daniel G. Diasio Lillian & Michael C. DiPiazza Kristen & Michael Dixon Lowell H. Dubrow Merigo & Thomas E. Durkin Marsha & George S. Faass Paula & David Fabbri Mary Jean Flannery Joan E. & Michael J. Foley Jean A. & Michael Fowler Grace & Henry C. Fung Tracy M. Gatto James Gillespie, Jr. Anne M. & Charles M. Gingrich Erica A. Golemis & Michael F. Ochs


Elaine I. & Sidney Grobman Jennifer & Christopher Hageman Diane T. & Robert J. Hansberry Kathyann Heilig Debra & Ronald Horrell Judy Chasin & Eric M. Horwitz Carol B. & Joseph Hummel Fadia & Jean-Pierre Issa Anne E. & John Jadwin Ruth Kaminer Arielle Kay Mark T. Kennedy Arnold Levin Vincent Maisano Ginny Martin & Robert Comis* Catherine McDevitt Christopher W. McNichol Arlene L. & Arthur Miller Suzanne Miller & Isaak Halegoua Judite Morais & Timothy Speiss Joyce & John P. Moran Kathleen & Francis X. Morris Alyssa Nyce & Joan M. Nyce Sameer A. Patel Tina M. Pidgeon & Timothy H. Fitzpatrick Eileen C. & Glenn F. Rall Elizabeth R. & Brian K. Rizor Lucyann M. & John J. Roley Sr. Shari & Mark Rosenberg Victoria D. Rosskam Corinne R. Roxby* Alycia & Thomas Scannapieco Elin R. Sigurdson & Drew Ridge Donna L. Skerrett Judith K. & Cecil D. Southard Marjorie Stanek Shirley E. & John E. Stoddard, III Peggy & Brian Strecker Erik F. Streitwieser Lisa & Peter R. Terreri Felicia R. Toska & Amanda Toska Cheryl D. & Robert G. Uzzo Margaret von Mehren & Eric G. Moss Lisa M. Wagner Christine Laine & David S. Weinberg Geraldine M. & William W. Weisser Robin A. & David L. Wiest Ingrid & Michael T. Yonker

PARTNER’S CIRCLE

$1,000 - $2,499

Melanie & Peter Adamo Robert Adams Evelyn Alameda Ruth & Thomas S. Albanesi, Jr. Michelle Albed Lorraine R. & Benjamin J. Alexander Lisa & Stanley J. Altman Anonymous Erlinda E. Apolinario Gerald F. Arleth Lisa Broida Bailey Diep & Siddharth Balachandran Suzanne & Richard Balbirer Dennis Barnes Mildred & John R. Barr Cassie Bartelme Marsha W. & John N. Beidler Lorraine S. & Robert C. Bell Robert J. Bennett Judith K. & Arnold M. Bernstein George M. Beschen Theresa & Richard M. Bobroski Mary Anne Bogie Marcia C. Boraas & Eugene Lugano Karrie L. Borgelt Ruth C. & Hossein Borghaei Ann & Alexander A. Bratic Marion B. Brody Ilene & Edward A. Bulanowski Patricia A.* & Robert C. Busby Devon E. & Todd A. Byers Roger L. Carroll Suzanne S. Castle Flo & Richard Celender Diane & Warren Chaiken Bernice & Robert P. Chast Kathy & David Y. Chen Lili Chen & Charlie Ma Cori & Michael J. Cherkas Lori & Michael Chewkanes Jeannine Chimbos & Michael Meacham Margie L. Clapper & Donald J. Carney, Jr. Joan R. & Frederick M. Cohen Edward Coleman

Susan Colucci Benjamin Compaine Denise C. Connolly & Ronald L. Wolf Richard M. Connolly, Sr. Fredi & Harry S. Cooper Margaret & Jay K. Crist Frank J. Crowley John Cupples Jayne Custer M. Walter D’Alessio Mary B. Daly & James L. Borders* Joy A. De Luca Maryann & Walter H. De Treux Antoinette & William DeCarlo Rose Marie A. Deffenbach Crystal S. Denlinger Emily Y. & Brian Denney Marie DeRatto & Alan R. Offermann Karen Diaddezio Patricia & Verdi J. Disesa Martin Dolan Arline & Ira R. Dolich Denise M. & Timothy J. Donahue Mohan Doss Tobe I. Dresner Vicki J. Markovitz & Larry Dubinski Allison & Michael G. Dubrow Rita E. & Charles E. Dunleavy, Jr. Sherri & Martin Edelman Pelaseyed Roshanak & Hormoz Ehya Dawn L. Elliott & Chris Balestrini Diane L. Entrikin Angelica G. & Eugene H. Eshbach Kathryn A. Evers Brande Mark & Frank Falzett Carolyn Y. Fang & John S. Shaw, III James Faust Annette & Lee S. Favorite Keith M. Ferko Anthony E. Fiorito Catherine M. & Edmund J. Florimont Amber L. & David C. Flynn Susan E. Johnson & James J. Flynn Richard T. Forchion Susanna & Daniel Forjohn Debra E. Fox Margaretha J. & Charles A. Fritz Anthony D. Genuardi Melinda B. & William German

P R EVA I L

Phyllis S. Gitlin Terri & Hyman Goldberg William R. Goldman Lori J. Goldstein & Mark Helmericks Julia Goplerud & Arland T. Hotchkiss, Jr. Marilou & David Greed Marianne T. & Donald T. Green Katherine M.* & Stanley A. Greene Elizabeth Kapnek Grenald Tina Martocello-Gricoski & John J. Gricoski Nancy L. Grove & Jim Bunderla Marlane C. & Harvey Guttmann Lynn Martin Haskin & Donald Haskin Margaret S. Havens Joyce E. & David B. Heinaman Kim D. & Theodore P. Heininger Amy H. & James L. Helstrom Alice C. Hennessy Geraldine A. & Thomas F. Henwood Harold G. Hepler Carla & Enrique Hernandez Evelyn Hernandez Joyce B. & Harvey D. Hertzler Jane E. Hollenbach Curtis J. Hoover Josette C. Horwath Marilyn Y. Hosang Amy E. & Alan G. Howald Herbert S. Howard Krisha & Christian Howell Kenneth A. Hullings James L. Hunsicker James E. Hyer John M. Hyman Barbara T. & Kevin Ilsen Tiel & George F. Ingersoll Athole Jacobi Karen E. & Bernard C. Jadach John M. Kaffenberg June & Marc Kantor James A. Kilduff James P. Kilkenny Walter C. Kinzinger Nicole T. & Kenneth Klein Melissa Kline Pamela Knight Kathy A. Kovacs

I NNOVAT I O N & I M PACT

23


Donors

Kristin K. & Thomas Krauss Thomas G. Kupp Jill & Charles D. Kurtzman Jeannine & James Lajeunesse Pauline Landis Joanne M. & Donald S. Laputka Anna & Ernest Larenz Lynn Lawrence Maureen R. & Gregory G. Lawton Jack Levin Laura & Daniel S. Levin Lynne & Andrew J. Levin Rhonda S. & Jeffrey S. Lichter Armand Liffman Rochelle M. & Charles Lobel William J. Logan Jerome Lomurno Arlene Lorch Irwin S. Love Dana L. Luca Lisa Kimbro & Ray Lynch Daniel D. Macey Sarah & Joe Maiellano Donna & Dan Malone Felix S. Mandato, Jr. Nancy M. & Felix S. Mandato, Sr. Angeline & Gerald J. Manna Jeffrey Markowitz Lainie Martin Maureen K. & Joseph McDade Christine A. & William McDonnell Kathryn Shively McKissock & J. Bruce McKissock Janet McMaster Michelle McMaster Aileen M. & Gary M. McQuarrie David R. McShane Dorothy & John E. Meggitt Steven A. Michaels Barton N. Milestone Amy L. Freedman & Michael M. Millenson Bonnie J. & Wayne Miller James W. Miller Judith F. & Myron Miller Keiko & George L. Miller Judith & James F. Mitchell, III Richard S. Molinaro Anselene M. Morris

24

Kathleen M. & Michael P. Moscufo Ruth M. & Preston L. Moyer Bridget & Michael D. Mulcahy Claire & Thomas J. Mulvaney Lori & Frederick G. Munizza John G. Nalesnik Sarah & Amir Naraghi Patricia S. & Robert S. Nase Deborah L. & Kirk J. Nemshick William A. Nickey Melanie J. Norris Elias Obeid Amy & Patrick J. O’Brien Lillian M. & Edward* O’Connor Katherine A. Odorow-Portnoy & Alan Portnoy Herbert Offenback Robert J. Orsher Richard M. Paczewski Heidi & Scot D. Pannepacker Catherine & Salvatore S. Paone Rosaleen & Rick Parsons Aris Pasles Pradeep R. Patel Doris L. Peck Patricia A. & Thomas W. Peddie Grace H. & James C. Peters Kathleen & Cameron C. Pitcairn Ellen R. & Jeffrey W. Plaut Elizabeth R. & David J. Plimack Susan M. & William R. Plunkett Margaret E. & Anthony C. Pratt Estelle & Stuart E. Price Valerie K. & Robert A. Price, Jr. Amanda K. Purdy & Thomas B. Cook Kim L. Rainey-Nichols & Scott J. Nichols Jessica & Marc Reider Cindy S. & Eric Resnick Adelina Riggione Jennifer & Joseph F. Riggione Richard C. Roden Fereshteh & Heinrich Roder Phyllis M. & Richard M. Rosenberg Jill S. & Norman G. Rosenblum Deborah K. & David E. Ross Jody Rosselle Jennifer Rupert Teena & Scott Russell

FOX CHA S E CA N CER CEN T ER

A N N UAL R EP O RT 20 17

Daphne Sawyer Tina Schechter Scott W. Scheffler Jessie Schol & Sarah Schol Marilyn & Alan C. Schwedel Kathleen Heaney & Kurt A. Schwinghammer Cecile H. Sculthorpe Elinor A. & Thomas Seaman Mark Searles Jean M. Seibel Helen Shank Jacqueline Shoukry Anna Marie & Rudolph Skalka Elaine & Mark L. Sobczak Cynthia & Howard S. Solganick Robin & John C. Spurlino Julia & Robert Steinberg Kristin & Kevin Sterling Zelda R. Stern Janice A. Stilley Ella J. & Erwin T. Straw Nancy L. & Raymond J. Svitak Pauline L. & Michael J. Sweeney Stephen B. Tanner Christine Taylor Robert S. Taylor Samuel T. Test Nelly B. & Hans Thalheimer Patricia Ellis & Rebecca Tillet James A. Tobin Dorothy M. & Edward Tosti, Jr. David J. Tsui Bradley S. Van Schooneveld Elizabeth & John H. Velardi Michelle & Robert Walper Maryanne Walsh Robert J. Wardrop Elizabeth & Robert Watts Miriam & Homer Weaver Stephanie Weiss & Hugh Mclaughlin Beatrice Wilkinson Welters & Anthony Welters Leigh A. Wetterau Kimberly & Daniel Williams Walter Williams Roger Winter Roni Wolfson Anthony J. Wong

Johnina C. & William S. Woods, Jr.* Harold W. Yahr Marcia A. & Jay Yanoff Karen & Bruce E. Young Barbara M. & Robert C. Young Yan Wang & Jian Q. (Michael) Yu Brenda & Arnold* Zaslow Susan S. & John Zuccotti

Corporations, Foundations & Organizations LEADER’S CIRCLE

$20,000 +

Asbestos Workers Local #14 Asbestos Workers Local #38 Mesothelioma Fund Fox Chase Cancer Center Board of Associates • Bucks County Chapter • Dan’s Voice Chapter • The Devlin Fund for Cancer Research • Marlyn R. Fein Chapter • Fox Chase Chapter • Friends of the Hospital of Fox Chase Cancer Center • Jimbo’s Squad Chapter • Main Line Chapter • Joseph J. Tiberi Memorial Fund E. Rhodes & Leona B. Carpenter Foundation The David Foundation Fifth District AHEPA Cancer Research Foundation GIST Cancer Research Fund Giflin Family Foundation Sandra Robyn Glaberson Foundation IAL, Inc. The Eileen Stein Jacoby Fund Kicking Cancer Foundation Susan G. Komen for the Cure Philadelphia The Edwin M. Lavino Foundation Lutron Electronics Co., Inc. Mid-Atlantic Packaging, Inc.


The Newport Foundation Inc. Tyanna Barre O’Brien Breast Cancer Foundation Sandy Rollman Ovarian Cancer Foundation The W. W. Smith Charitable Trust The Snider Foundation United Way of Greater Philadelphia & Southern New Jersey Uplifting Athletes West DragonPhyre West Pharmaceutical Services, Inc. Wright-Cook Foundation

FRIEND’S CIRCLE

$5,000 - $19,999

AbbVie Pharmaceuticals Abington Friends School Albidale Old Timers Association Anonymous ARIAD Pharmaceuticals Bill Aust Scholarship Fund BlackRock The Brenda Trust Bristol-Myers Squibb Broughton Foundation C.W.A. Local 13000 Digital Science Press Inc. The Marianne DiNofrio Pancreatic Research Foundation Duane Morris LLP Eisai Inc. Exelon Foundation The Walter Henry Freygang Foundation Christopher Fuga Memorial Fund Genentech, Inc. Dr. Meyer Glickman Memorial Fund Harmelin Media Rita R. Holman Breast Cancer Foundation, Inc. Incyte Corporation Oscar H. & E. Ida Iucker Memorial Fund Johnson & Johnson The Kanter Foundation Kite Pharma, Inc. Kohlhepp Investment Advisors

LAOH Brigid McCrory Division 25 M. R. Rose Construction, Inc. Mary K. Dougherty LTD The McGrorty Foundation, Inc. Merck Foundation Montgomery County Community College Mutual of America Foundation NeoGenomics Laboratories, Inc. New Hope Auto Show Norristown Bocce League The Oklahoma City Zoo Out of the Blue Productions Phoenixville Country Club Rogers Rissler Foundation Rob’s Fight Against Cancer Sanofi Foundation for North America Sarcoma Foundation of America, Inc. Schultz & Williams Charles Schwab Corporation Foundation Seattle Genetics Tanner Industries, Inc. TESARO, Inc. TEVA Pharmaceuticals USA Ukrainian American Sports Center Vertical Bridge REIT, LLC YourCause, LLC Trustee

Elizabeth Anderson Society Honors individuals who have included Fox Chase Cancer Center in their estate plans. Caonabo F. Almonte Suzanne B. Balbirer Raymond Bartolacci Toni-Lee Beigel Catherine & Walter G. Bittner Kay & Mike Breuninger Cheryl I. Brown Kathleen Bullano Robert C. Busby Christina M. & Ernesto A. Canales Jane P. & Kenneth B. Charlesworth Donna J. Cochran Margaret A. & Thomas A. Coughlin Robert J. Cronk

Maureen E. & J. Russell Cullen Lia M. Skillern & Theodore S. Dalstrom Elizabeth & John Dambrowski Emily M. Dannaker Helen R. Davis Nancy S. Day Carol A. & Louis E. Della Penna, Sr. Linda & Robert Devlin Arline L. & Ira R. Dolich Sondra Doner Kendra B. Eager Yvonne L. Eldridge Carol Elfant Beth K. Kocher-Ferraro & Frank Ferraro Louise Perow Flurer Barbara R. & Alfonse J. Gabriele Helen J. & Thomas Gebhardt Catherine R. Getchell Nancy E. Goldy Concetta Greenberg Stanley A. Greene Elizabeth K. & Raymond Grenald Edith D. & Frank M. Highley Eleanor J. Hillegas Lois N. Hitchman Jane E. Hollenbach Alice M. Hungerford David P. Ineich Alma R. Jacobs Nancy & Rodney D. Johnson Joan E. Jones Mary Ann Jones Barbara R. & Charles Kahn, Jr. Margot Wallace Keith & Robert E. Keith, Jr. Gwendolyn S. King & Colbert I. King Janet C. Kistner Janet B. Kovacs Geraldine M. Kozempel Martha J. & R. Donald Leedy Michael Levin Wendy & Andrew L. Lewis Naomi & Philip E. Lippincott Susan & William G. Little Amy Lowenstein Nancy & M. Michael Markowich Richard B. Millham

P R EVA I L

Cathie M. Minehart Beatrice Mintz Judith A. & James F. Mitchell, III Diane & David M. Morgan Michael J. Nauss Elma & Edward R. Neeld Diane W. Nyland Kaye & Merrill D. Paletz Sandra L. Paugh Wenona & Raymond A. Paul Sally Peirson Jane G. Pepper Beatrice C. Pilch Irma S. Platnick Clare K. Porac Joanne & Alexander Rankin Dolores Renneberg Edward J. Roach Suzanne & Norman T. Robinson Richard C. Roden Jayne H. & Paul I. Rosen Lynne H. Rosenbaum John Ruggio Rev. Cecily J. Sawyer Harmon Carol Schramek Karen Schwartz Josephine & John Scully Mark Sigismund Louise A. Sonnenberg Barbara L. Sparks Zuzanna L. & Roger J. Stankay Bonnie Stock Evelyn J. Swarttz Nancy K. Switzer Norma Tither Wendy Trow-Fox & Remy L. Fox Adele E. Veihl Anna Vinerova George D. Wasserberger Norman F. Watts Sandra W. & Timothy C. Weckesser Naomi Weiss Kenneth L. Williams Justin L. Young

* Deceased donors

I NNOVAT I O N & I M PACT

25


Financials

2017 BY THE NUMBERS

111,468 OUTPATIENT VISITS

8,864 NEW PATIENTS

265

CLINICAL TRIALS

12

NEW FACULTY MEMBERS

589

SCIENTIFIC PUBLICATIONS

VOLUNTEER SNAPSHOT

524

PHILANTHROPY SNAPSHOT

$14,300,849

TOTAL PHILANTHROPIC SUPPORT

$2,031,211 RAISED AT IN VINO VITA

TYPES OF CANCERS TREATED

3% 4% 4%

7,712

5%

2,894

6%

TOTAL DONORS Â

TOTAL NEW DONORS

233

CURRENT DONORS WHO HAVE GIVEN 30+ YEARS

$288,826

BOARD OF ASSOCIATES TOTAL GIFTS

6% 7% 10%

PANCREAS HEAD & NECK LYMPHOMA

BLADDER

KIDNEY

SKIN

COLORECTAL

GYNECOLOGICAL

VOLUNTEERS

94,072

TOTAL VOLUNTEER HOURS

$249,648

VOLUNTEER DEPARTMENT BUDGET

$2,270,898 VALUE OF HOURS

$2,021,250

NET VALUE ADDED TO FOX CHASE

265

ACTIVELY ENROLLING INVESTIGATOR INITIATED CLINICAL TRIALS

83

ACTIVELY ENROLLING CLINICAL RESEARCH STUDIES

Numbers represent Fiscal Year 2017

26

FOX CHA S E CA N CER CEN T ER

A N N UAL R EP O RT 20 17

10% 16% 16% 14%

LUNG

PROSTATE

BREAST

OTHER


RESEARCH SNAPSHOT

ACTIVE FUNDED PROJECTS Funding Source

Number of Projects

Direct Costs

Total Costs

92 78 30

$13,767,732 $13,305,523 $4,105,219

$21,686,339 $19,790,589 $5,704,151

200

$31,178,474

$47,181,079

85 28

$15,795,522 $2,408,187

$20,260,882 2,816,169

Subtotal of non peer-reviewed

113

$18,382,709

$23,077,051

GRAND TOTAL

313

$49,382,183

$70,258,130

PEER-REVIEWED NCI Other NIH Other Subtotal of peer-reviewed NON PEER-REVIEWED Industry Other non peer-reviewed

CLINICAL SNAPSHOT (In Thousands) FY17

REVENUES – CLINICAL ACTIVITY Patient Care Revenue – Hospital Patient Care Revenue – Physicians Philanthropy, Outreach & Other

$336,186 $33,256 $11,806

Clinical Revenue

$381,248

OPERATING EXPENSES – CLINICAL ACTIVITY Direct Patient Care Support Services Administrative and General Capital Related Costs Maintenance and Plant Operations

$256,839 $18,529 $41,107 $10,354 $10,534

Clinical Expenses

$337,363

KEY PATIENT CARE STATISTICS New Patients Hospital Admissions Chemotherapy Infusions and Related Procedures Radiation Therapy Treatments

8,864 4,210 60,594 25,347

FY17 PAYER MIX

Q

COMMERCIAL

42%

Q

MEDICARE

38%

Q

MEDICARE MANAGED CARE

11%

Q

MEDICAID

8%

Q

SELF-PAY/OTHER

1%

P R EVA I L

I NNOVAT I O N & I M PACT

27


Leadership & Faculty

SENIOR ADMINISTRATORS Richard I. Fisher, MD President and Chief Executive Officer Cancer Center Director Senior Associate Dean, Lewis Katz School of Medicine at Temple University

Larry R. Kaiser, MD Margot Wallace Keith Robert H. LeFever Solomon C. Luo, MD David G. Marshall Christopher W. McNichol Donald E. Morel Jr., PhD Leon O. Moulder Jr. Donna L. Skerrett, MD

FOX CHASE CANCER CENTER FOUNDATION BOARD OF DIRECTORS

J. Robert Beck, MD Deputy Director Chief Academic Officer Chief Administrative Officer

Jonathan Chernoff, MD, PhD Deputy Director Chief Scientific Officer

Wafik S. El-Deiry, MD, PHD Deputy Cancer Center Director for Translational Research

Judith L. Bachman, RN, BSN Chief Operating Officer

Ray Lynch, MBA, CPA Chief Financial Officer

James Helstrom, MD, MBA Chief Medical Officer

Anne Jadwin, RN, MSN Chief Nursing Officer

Chair: Donald E. Morel Jr., PhD Vice Chair: Louis E. Della Penna Sr. Ira R. Dolich William J. Federici Richard I. Fisher, MD Edward A. Glickman Lewis F. Gould Jr. Thomas W. Hofmann Barbara Ilsen Margot Wallace Keith Geoffrey Kent Dan Levin Philip E. Lippincott Solomon C. Luo, MD David G. Marshall Edward J. Roach Lindy Snider Thomas R. Tritton, PhD

Interim Chief Development Officer

Chair: Lewis F. Gould Jr. John M. Daly, MD Mary B. Daly, MD, PhD Verdi J. DiSesa, MD Ronald R. Donatucci William J. Federici Edward A. Glickman Lon R. Greenberg Kimberly D. Hagerich Thomas W. Hoffman

28

TIMOTHY R. TALBOT JR. CHAIR IN CANCER RESEARCH

Martin J. Edelman, MD

Mary B. Daly, MD, PhD, FACP

Chair, Department of Hematology/Oncology

Chair, Department of Clinical Genetics

MARVIN S. GREENBERG, M.D. CHAIR IN PANCREATIC CANCER SURGERY

CAROL & KENNETH WEG CHAIR IN HUMAN GENETICS

John P. Hoffman, MD, FACS

Joseph R. Testa, PhD, FACMG

Chief, Pancreaticobiliary Service

Co-Leader, Cancer Biology Program

PAUL GROTZINGER & WILBUR RAAB CHAIR IN SURGICAL ONCOLOGY

Stephen C. Rubin, MD Chief, Division of Gynecologic Oncology

AUDREY WEG SCHAUS & GEOFFREY ALAN WEG CHAIR IN MEDICAL SCIENCE

David S. Weinberg, MD, MSc Chair, Department of Medicine

SAMUEL M.V. HAMILTON CHAIR IN CANCER PREVENTION

Paul F. Engstrom, MD, FACP Chief, Section of General Hematology/Oncology GERALD E. HANKS CHAIR IN RADIATION ONCOLOGY

H.O. WEST & J.R. WIKE CHAIR IN CANCER RESEARCH

J. Robert Beck, MD Chief Academic and Administrative Officer

Eric M. Horwitz, MD

ROBERT C. YOUNG, M.D. CHAIR IN CANCER RESEARCH

Chair, Radiation Oncology

Richard I. Fisher, MD

G. WILLING “WING” PEPPER CHAIR IN CANCER RESEARCH

Robert G. Uzzo, MD, FACS Chair, Department of Surgical Oncology

President and Chief Executive Officer

PENDING APPOINTMENTS THE GLORIA & EDMUND M. DUNN

FOX CHASE CANCER CENTER ENDOWED CHAIRS

Catherine D. Bartelme

BOARD OF DIRECTORS

G. MORRIS DORRANCE JR. CHAIR IN MEDICAL ONCOLOGY

STANLEY P. REIMANN CHAIR IN ONCOLOGY RESEARCH

Drew Ridge, MD, PhD, FACS Chief, Head and Neck Surgery

Beatrice Mintz, PhD Professor, Cancer Biology

Richard E. Greenberg, MD, FACS Professor, Department of Surgical Oncology

FOX CHA S E CA N CER CEN T ER

A N N UAL R EP O RT 20 17

THE DONALD E. & SHIRLEY C. MOREL, STANLEY & STELLA

JACK SCHULTZ CHAIR IN BASIC SCIENCE

CAROL & LOUIS DELLA PENNA CHAIR IN UROLOGIC ONCOLOGY

ONCOLOGY

Jonathan Chernoff, MD, PhD Chief Scientific Officer

LOUIS DELLA PENNA FAMILY CHAIR IN HEAD AND NECK ONCOLOGY

CHAIR IN THORACIC SURGICAL

BAYSTER CHAIR IN MOLECULAR IMAGING

CLINICAL FACULTY

WILLIAM WIKOFF SMITH CHAIR IN CANCER RESEARCH

DEPARTMENT OF CLINICAL GENETICS

Wafik El-Deiry, MD, PhD, FACP

Chair: Mary B. Daly, MD, PhD Michael J. Hall, MD, MS Elias Obeid, MD, MPH

Deputy Cancer Center Director, Translational Research Program


DEPARTMENT OF DIAGNOSTIC IMAGING

Chair: Rosaleen Parsons, MD Sarah Abdulla, MD Jesty Abraham, DO Jordan Anaokar, MD Marion Brody, MD Mark Burshteyn, MD 7 Gary Cohen, MD 7 Emily Cuthbertson, MD 7 Kathryn Evers, MD Marlane C. Guttmann, MD Barton Milestone, M.D Dmitry Niman, MD 7 Joseph Panaro, MD 7 Joseph Perno, MD, PhD David Pryluck, MD 7 Catherine Tuite, MD Rohit Walia, MD Jian Qin Yu, MD

Anthony J. Olszanski, MD, RPh Philip Pancari, MD Elizabeth Plimack, MD Carlyn Tan, MD Joseph Treat, MD Namrata Vijayvergia, MD Margaret von Mehren, MD Jennifer Winn, MD Matthew Zibelman, MD

PSYCHIATRY

PAIN AND PALLIATIVE CARE

DEPARTMENT OF PATHOLOGY

Marcin Chwistek, MD Molly E. Collins, MD

Chair: Arthur S. Patchefsky, MD Essel Al-Saleem, MD Tahseen Al-Saleem, MD J. Robert Beck, MD Christine Burgert-Lon, DO Harrry S. Cooper, MD Andrew Czulewicz, MD Hormoz Ehya, MD Douglas Flieder, MD Yulan Gong, MD Min Huang, MD Rajeswari Nagarathinam, MD Shuanzeng Wei, MD, PhD Hong Wu, MD, PhD

FOX CHASE CANCER CENTER AT TEMPLE UNIVERSITY HOSPITAL

Juhi Mittal, MD Aruna Padmanabhan, MD Alvaro Pereira-Rico, MD Deric Savior, MD

DEPARTMENT OF HEMATOLOGY/ONCOLOGY

DEPARTMENT OF MEDICINE

Chair: Martin J. Edelman, MD Igor Astsaturov, MD, PhD Stefan Barta, MD Jessica Bauman, MD Hossein Borghaei, DO Yanis Boumber, MD, PhD Robert Carlson, MD Jonathan Cheng, MD Crystal Denlinger, MD Efrat Dotan, MD Scot Ebbinghaus, MD Wafik S. El-Deiry, MD, PhD Paul F. Engstrom, MD Richard I. Fisher, MD Henry Fung, MD Vijaykumar Gandhi, MD Daniel Geynisman, MD Lori J. Goldstein, MD Angela Jain, MD Nadia Khan, MD Rashmi Khanal, MD Patricia Kropf, MD Gregory Lubinieki, MD Lanie Martin, MD Michael Millenson, MD Sujana Movva, MD

CARDIOLOGY

Chair: David S. Weinberg, MD Steven Mattleman, MD

Emmie Chen, MD Paula Finestone, PhD Craig Lichtman, MD Michelle Rodoletz, PhD PULMONARY MEDICINE

Alan Haber, MD Rohit Kumar, MD Christopher Manley, MD

DERMATOLOGY

ANESTHESIOLOGY

Abhishek Aphale, MD Anthony Santoro, MD

DEPARTMENT OF RADIATION ONCOLOGY

ENDOCRINOLOGY

Chair: Eric M. Horwitz, MD Penny Anderson, MD Jo Ann Chalal, MD3 Thomas Galloway, MD Mark Hallman, MD Shelly Hayes, MD Krisha Howell, MD Joshua Meyer, MD Mark Sobczak, MD Stephanie Weiss, MD

Pankaj Sharda, MD Colleen Veloski, MD GASTROENTEROLOGY

Michael Bartel, MD Minhhuyen Nguyen, MD Jeffrey Tokar, MD HOSPITALISTS

Daniel Holleran, MD Kyungsuk Jung, MD Kristen Manley, MD Kenneth Patrick, MD Rajkumar Sarkar, MD Krishnalatha Sreekrishnanilayam Devakiamma, MD MD Usmna Ali, MD Hayley Walker, MD PHYSICAL MEDICINE AND REHABILITATION

Gilbert Lafontant, MD

Christina Chu, MD Paul Curcillo, MD John Michael Daly, MD Nestor F. Esnaola, MD Jeffrey Farma, MD Christopher Fundakowski, MD Richard E. Greenberg, MD John Handal, MD John P. Hoffman, MD Nausheen Jamal, MD Andreas Karachristos, MD Stephanie King, MD Alexander Kutikov, MD Miriam Lango, MD Jeffrey Liu, MD Gina Mantia-Smaldone, MD Sameer Patel, MD Sanjay Reddy, MD Drew Ridge, MD, PhD Stephen Rubin, MD Elin Sigurdson, MD, PhD Marc Smaldone, MD Stacey Su, MD Neal Topham, MD Rosalia Viterbo, MD Valerie Armstead, MD James L. Helstrom, MD Kristen K.G. Krauss, MD Scott Levin, MD Michelle McMaster, MD Gupreet Mundi, MD Vaishali Naik, MD Dmitry Roberman, DO Felipe Suero, MD

RESEARCH FACULTY BLOOD CELL DEVELOPMENT AND FUNCTION

DEPARTMENT OF SURGICAL ONCOLOGY

PROGRAM LEADERS

Chair: Robert G. Uzzo, MD Abbas El-Sayed Abbas, MD John Abraham, MD Allison Aggon, DO Cynthia Bergman, MD Richard Bleicher, MD Marcia Boraas, MD David Chen, MD

Siddharth Balachandran, PhD David L. Wiest, PhD PRIMARY MEMBERS

Stefan Barta, MD6 Kerry S. Campbell, PhD Richard I. Fisher, MD6 Henry Fung, MD6 Stefania Gallucci, MD7

P R EVA I L

I NNOVAT I O N & I M PACT

29


Leadership & Faculty

Kyoko Hayakawa, MD, PhD Liselotte E. Jensen, PhD7 Dietmar J. Kappes, PhD Ekaterina Koltsova, PhD Dan A. Liebermann, PhD7 Xuebin Qin, MD, PhD7 Glenn Rall, PhD Jennifer Rhodes, PhD Christoph Seeger, PhD Anna M. Skalka, PhD Tomasz Skorski, MD, PhD, DSc7 Jonathan Soboloff, PhD7 Stephen M. Sykes, PhD Yibin Yang, PhD Raza M. Zaidi, PhD7 Matthew Zibelman, MD6 CANCER BIOLOGY PROGRAM LEADERS

Jonathan Chernoff, MD, PhD Joseph R. Testa, PhD PRIMARY MEMBERS

Edna Cukierman, PhD James S. Duncan, PhD Joan Font-Burgada, PhD Bojana Gligorijevic, PhD7 Lawrence Goldfinger, PhD Jennifer Gordon, PhD7 Xavier Graña, PhD Raymond Habas, PhD7 Tiffiney Hartman, PhD Andres J.P. Klein-Szanto, MD, PhD Vladimir Kolenko, MD, PhD Warren D. Kruger, PhD Jeffrey R. Peterson, PhD Richard T. Pomerantz, PhD7 Jose Russo, PhD Hong Yan, PhD Zeng-jie Yang, MD, PhD Timothy J. Yen, PhD MOLECULAR THERAPEUTICS PROGRAM LEADERS

Wafik S. El-Deiry, MD, PhD6 Erica A. Golemis, PhD PRIMARY MEMBERS

Philip Abbosh, MD, PhD Rodrigo Andrade, PhD7 Mark Andrake, PhD

30

Igor Astsaturov, MD, PhD6 Hossein Borghaei, DO6 Yanis Boumber, MD, PhD Denise C. Connolly, PhD Roland L. Dunbrack Jr., PhD Brian L. Egleston, PhD Lori J. Goldstein, MD6 Harvey Hensley, PhD Eric Horwitz, MD6 Eileen K. Jaffe, PhD Neil Johnson, PhD John Karanicolas, PhD Kamel Khalili, PhD7 Nadia Khan, MD6 Michael L. Klein, PhD7 Ronald Levy, PhD7 Jeffrey C. Liu, MD7 Lainie P. Martin, MD6 Salim Merali, PhD7 Joshua Meyer, MD6 Anthony J. Olszanski, MD, RPh6 Alana O’Reilly, PhD Drew Ridge, MD, PhD6 Lori Rink, PhD Heinrich Roder, PhD Elin R. Sigurdson, MD, PhD6 Vincent A. Voelz, PhD7 Margaret von Mehren, MD6 Ross Wang, PhD Ho-Lun Wong, PhD7 Jinhua Wu, PhD Michael Yu, MD6 CANCER PREVENTION AND CONTROL PROGRAM LEADERS

Margie L. Clapper, PhD Carolyn Y. Fang, PhD

Sergei Grivennikov, PhD Michael J. Hall, MD6 Michael Halpern, MD, PhD7 Carolyn J. Heckman, PhD Enrique Hernandez, MD7 Stephen Lepore, PhD7 Shannon Lynch, PhD Grace X. Ma, PhD7 Suzanne M. Miller, PhD Elias Obeid, MD6 Camille Ragin, PhD Jennifer Reese, PhD Laura Siminoff, PhD7 David S. Weinberg, MD6 Kuang-Yi Wen, PhD

The Annual Report is produced by the Communications Department of Fox Chase Cancer Center. Contact us at editor@fccc.edu. Temple Health refers to the health, education and research activities carried out by the affiliates of Temple University Health System (TUHS) and by The Lewis Katz School Temple University School of Medicine. TUHS neither provides nor controls the provision of health care. All health care is provided by its member organizations or independent health care providers affiliated with TUHS member organizations. Each TUHS member organization is owned and operated pursuant to its governing documents.

CANCER EPIGENETICS PROGRAM LEADERS

Jean-Pierre J. Issa, MD7 Vasily M. Studitsky, PhD

Jeremy Moore Senior Director of Communications

PRIMARY MEMBERS

Andrew Becker

Andrew J. Andrews, PhD Alfonso Bellacosa, MD, PhD Paul Cairns, PhD Xiaowei Chen, PhD Nora Engel, PhD7 Shan He, PhD7 Jian Huang, MD, PhD7 Jaroslav Jelinek, MD, PhD7 Richard A. Katz, PhD Patricia L. Kropf, MD6 Elizabeth R. Plimack, MD6 Carmen Sapienza, PhD7 Bassel E. Sawaya, PhD7 Italo Tempera, PhD7 Alexei Tulin, PhD Hong Wang, MD, PhD7 Yi Zhang, MD, PhD7

Director of External Communications

Rachel D’Ascendis Editorial Assistant

Paige Allen Staff Writer

Writers & Contributors Paige Allen Rachel D’Ascendis Jill Horne

Photography Colin Lenton

Cover Illustration Bryan Christie

Design

PRIMARY MEMBERS

Sanjeevani Arora, PhD J. Robert Beck, MD6 Bradley N. Collins, PhD7 Mary B. Daly, MD, PhD6 Efrat Dotan, MD7 Paul F. Engstrom, MD6 Nestor F. Esnaola, MD6 Susan Gross Fisher, PhD7 Ana M. Gamero, PhD7 Daniel Geynisman, MD6

FOX CHA S E CA N CER CEN T ER

A N N UAL R EP O RT 20 17

B&G Design Studios 1

2

3

4

Member of the Temple University Health System Interventional Radiology team Attending Physician, Atlanti-Care Cancer Care Institute, Cape May Courthouse and Egg Harbor Township, NJ Attending Physician, Urology Health Specialists Prostate Cancer Center, Plymouth Meeting, PA Attending Physician, Academic Urology Prostate Center, King of Prussia, PA

Printing Brilliant Graphics

5

6

7

Attending Physician, Virtua Fox Chase Cancer Center Radiation Oncology, Washington Township, NJ Member of the Fox Chase Cancer Center clinical faculty Faculty based at Temple University


NON-PROFIT ORG. U.S. POSTAGE

PAID PHILADELPHIA, PA

333 Cottman Avenue Philadelphia, PA 19111-2497 www.foxchase.org 1-888-FOX-CHASE

Comprehensive Cancer Center A Cancer Center Designated by the National Cancer Institute

PERMIT NO. 3187

Connect with us online! Visit annualreport.foxchase.org

Profile for Temple Health

Fox Chase Cancer Center - Annual Report 2017  

Fox Chase Cancer Center - Annual Report 2017

Fox Chase Cancer Center - Annual Report 2017  

Fox Chase Cancer Center - Annual Report 2017